How to Respond to FDA Form 483s and Warning Letters
July 10, 2017
Many medical device manufacturers receive FDA warning letters due to lack of preparation for the FDA inspection and/or an inadequate response to an FDA Form 483.
The manner in which manufacturers respond to the 483 is critical in mitigating potential compliance risks and preventing the issuance of a warning letter. This article by NSF’s Kristen Grumet, published in Medical Design and Outsourcing, explains six key steps manufacturers can take when issued the FDA Form 483.
How NSF Can Help You
Get in touch to find out how we can help you and your business thrive.
What’s New with NSF
NSF Launches Protocol 549 for Glyphosate Reduction Claims
October 14, 2026P549 is the first standard globally that validates glyphosate reduction performance of water filtration systems and products.
Cambium Analytica, an NSF Company, Opens New Lab in Traverse City, Mich
October 6, 2026Ribbon cutting debuts innovative 15,000-square-foot testing facility to support evolving needs of the food & supplement industries.
NSF Drives Industry Conversations at SupplySide Global 2026 - Las Vegas, Oct. 26–30
September 17, 2026NSF returns to SupplySide Global with expert-led training and trusted certification solutions. Visit Booth 4741 to discover how NSF and Cambium Analytica help brands build trust, increase consumer confidence and stand out in a competitive marketplace.
NSF Welcomes Hanjun Kwon, Managing Director, APAC
September 14, 2026Experienced business leader to drive sustainable growth, organizational development and operational excellence across the Asia-Pacific region.